CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS

Genomic studies of tumor specimens are becoming standard of care in patients with gliomas to characterize druggable molecular features. Unfortunately, with the exception of IDH1-R132 mutation and MGMT promoter methylation, molecular markers have failed to predict clinical responses to drugs, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Blitz, Sarah, Dominas, Christine, Pannell, Michael J, Chiocca, E Antonio, Wen, Patrick Y, Jonas, Oliver, Peruzzi, Pierpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453850/
http://dx.doi.org/10.1093/noajnl/vdab112.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453850/
http://dx.doi.org/10.1093/noajnl/vdab112.004

Ejemplares similares